Dabrafenib–Panobinostat Salt: Improving the Dissolution Rate and Inhibition of BRAF Melanoma Cells
Open Access
- 8 May 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (20) , 18255-18265
Abstract
Cocrystallization of the drug–drug salt-cocrystal of the histone deacetylase inhibitor (HDACi) panobinostat (PAN) and b-rapidly accelerated fibrosarcoma (BRAF) inhibitor dabrafenib (DBF) afforded single crystals of a two-drug salt stabilized by N+–H···O and N+–H···N– hydrogen bonds between the ionized panobinostat ammonium donor and dabrafenib sulfonamide anion acceptor in a 12-member ring motif. A faster dissolution rate for both drugs was achieved through the salt combination compared to the individual drugs in an aqueous acidic medium. The dissolution rate exhibited a peak concentration (Cmax) of approximately 310 mg cm–2 min–1 for PAN and 240 mg cm–2 min–1 for DBF at a Tmax of less than 20 min under gastric pH 1.2 (0.1 N HCl) compared to the pure drug dissolution values of 10 and 80 mg cm–2 min–1, respectively. The novel and fast-dissolving salt DBF–·PAN+ was analyzed in BRAFV600E melanoma cells Sk-Mel28. DBF–·PAN+ reduced the dose–response from micromolar to nanomolar concentrations and lowered IC50 (21.9 ± 7.2 nM) by half compared to PAN alone (45.3 ± 12.0 nM). The enhanced dissolution and lower survival rate of melanoma cells show the potential of novel DBF–·PAN+ salt in clinical evaluation.Keywords
Funding Information
- University Grants Commission
- Anusandhan National Research Foundation (2016/001632)
- Department of Science and Technology, Ministry of Science and Technology, India (SR/S2/JCB-06/2009)
- National Chemical Laboratory
This publication has 44 references indexed in Scilit:
- Chronic kidney disease: global dimension and perspectivesThe Lancet, 2013
- Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3Cell Death & Disease, 2013
- Melanoma: New Insights and New TherapiesJournal of Investigative Dermatology, 2012
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature, 2010
- First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic ReviewJournal of Thoracic Oncology, 2010
- Cardiovascular Disease Risk Factors: Epidemiology and Risk AssessmentThe American Journal of Cardiology, 2010
- Universal risk factors for multifactorial diseasesEuropean Journal of Epidemiology, 2007
- Mutations of the BRAF gene in human cancerNature, 2002
- Global and societal implications of the diabetes epidemicNature, 2001
- Encoding and decoding hydrogen-bond patterns of organic compoundsAccounts of Chemical Research, 1990